RecruitingObesityOverweight
Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)
Eligible age
18–70 yrs
Accepts
All genders
Locations
7 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The primary purpose of the study is to assess the pharmacokinetics of maridebart cafraglutode after switching from weekly GLP-1RA in participants living with overweight or obesity.
Sponsor: Amgen
You may qualify if…
- ✓ 18 to 70 years of age.
- ✓ Body Mass Index (BMI) ≥ 25 at screening.
- ✓ BMI ≥ 23 for Asian participants at screening.
- ✓ Stable body weight (approximately 5% or less gain or loss) during the 4-week run-in period, unless the study doctor determines otherwise.
- ✓ Stable dose of weekly GLP-1RA.
- ✓ Stable gastrointestinal (GI) tolerability.
- ✓ Contraception for females.
- ✓ Stable for 3 months if obstructive sleep apnea (OSA), hypertension, hyperlipidemia, and/or hypothyroidism.
You may not qualify if…
- ✕ Type 1/Type 2 diabetes mellitus (DM).
- ✕ Obesity induced by other endocrine disorder (ex: Cushing's syndrome).
- ✕ History of malignancy in the last 5 tears except for nonmelanoma skin cancers, cervical, or breast ductal carcinoma in situ.
- ✕ Acute \& chronic pancreatitis within 1 year.
- ✕ Uncontrolled thyroid disease.
- ✕ Gastroparesis or gastric outlet obstruction.
- ✕ Surgery for obesity in the last 6 months.
- ✕ Heart attack within 3 months.
Where it's recruiting
Source: ClinicalTrials.gov · NCT07908316 · last updated 2026-11-02